Bedfont Scientific Appoints Michael Bencak To Board To Accelerate Global Expansion In Breath Analysis Market

Med-tech leader Bedfont Scientific appoints Michael Bencak to its board to drive international growth and scale its global breath analysis technology.

By: AXL Media

Published: Mar 17, 2026, 12:03 PM EDT

Source: Information for this report was sourced from Bedfont® Scientific Ltd

Strengthening Leadership for a New Era of Medical Technology

Bedfont Scientific, a prominent global player in the specialized field of breath analysis, has announced a strategic addition to its leadership team with the appointment of Michael Bencak to its board of directors. This move comes as the company celebrates nearly five decades of designing and manufacturing non-invasive medical devices that assist in clinical investigations and patient diagnoses. According to Jason Smith, CEO of Bedfont, the inclusion of Bencak is a deliberate step to bolster the company’s internal expertise as it navigates a phase of rapid development and seeks to solidify its status as a world leader in respiratory diagnostics.

A Decades Long Legacy of Life Science Expertise

Michael Bencak enters the role with over 20 years of experience in leading and building organizations within the global healthcare and life science sectors. His professional history is defined by a strategic approach to unlocking business potential and managing complex international expansions. By bringing this level of veteran leadership to the board, Bedfont aims to refine its corporate strategy and navigate the regulatory and logistical challenges of entering new global markets. This expertise is expected to be instrumental in moving the company closer to its goal of providing universal access to instant, simple breath testing for medical professionals.

Scaling Operations Following Major Capital Investment

The appointment of Bencak is closely linked to the company’s recent financial trajectory, specifically following the 2025 acquisition of a majority stake in the business by Keensight. This influx of capital and change in ownership structure has set the stage for an accelerated growth phase, requiring a board capable of managing large-scale global partnerships. The company currently operates through a network of over 100 distributors worldwide, and Bencak’s track record in scaling medical device businesses is seen as a vital asset for optimizing this extensive international supply chain.